CellSeed Inc. (JP:7776)
:7776
Want to see JP:7776 full AI Analyst Report?
7776 Stock Chart & Stats
¥259.00
-¥7.00(-1.73%)
At close: 4:00 PM EST
¥259.00
-¥7.00(-1.73%)
Day’s Range― - ―
52-Week Range¥231.00 - ¥597.00
Previous CloseN/A
Volume900.50K
Average Volume (3M)621.90K
Market Cap
¥10.53B
Enterprise Value¥7.80B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.27
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.31
Shares Outstanding38,987,920
10 Day Avg. Volume981,780
30 Day Avg. Volume621,903
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Healthy Gross MarginsSustained gross margins near 48%–69% indicate solid unit economics for CellSeed’s products and services. This margin strength supports long-term product viability, pricing power in niche regenerative medicine, and the potential to leverage scale to fund R&D or manufacturing investments.
Conservative LeverageLow debt-to-equity provides structural financial flexibility, reducing bankruptcy risk and preserving the ability to raise capital on better terms. For a clinical-stage biotech, conservative leverage helps absorb development volatility and supports continued R&D and regulatory programs without onerous interest burdens.
Core Technology FocusA focused platform in cell-sheet engineering and regenerative therapies provides a durable competitive edge through specialized know-how and manufacturing capability. This niche expertise can create high barriers to entry, differentiated product opportunities, and long-term service revenue from development/manufacturing partnerships.
Bears Say
Persistent Cash BurnContinuous negative operating and free cash flows signal the business cannot self-fund operations and development. Persistent burn increases dependence on external financing, raising dilution risk and constraining long-term strategy, especially if clinical timelines or commercialization take longer than anticipated.
Revenue DeteriorationA sudden 56.7% revenue decline reflects weak commercial traction or one-off contract losses, undermining the revenue base required to absorb fixed costs. Without a clear, durable recovery in top-line, the company faces structural margin pressure and a prolonged funding gap for development programs.
Large Operating Losses & Equity ErosionExtremely negative margins and declining equity indicate sustained unprofitability and potential dilution to finance operations. Deep losses erode stakeholder value and can impair hiring, partnerships, and long-term R&D investment capacity unless a credible path to profitability or meaningful financing is established.
CellSeed Inc. News
7776 FAQ
What was CellSeed Inc.’s price range in the past 12 months?
CellSeed Inc. lowest stock price was ¥231.00 and its highest was ¥597.00 in the past 12 months.
What is CellSeed Inc.’s market cap?
CellSeed Inc.’s market cap is ¥10.53B.
When is CellSeed Inc.’s upcoming earnings report date?
CellSeed Inc.’s upcoming earnings report date is May 13, 2026 which is in 10 days.
How were CellSeed Inc.’s earnings last quarter?
CellSeed Inc. released its earnings results on Feb 13, 2026. The company reported -¥7.31 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.31.
Is CellSeed Inc. overvalued?
According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued.
Does CellSeed Inc. pay dividends?
CellSeed Inc. does not currently pay dividends.
What is CellSeed Inc.’s EPS estimate?
CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSeed Inc. have?
CellSeed Inc. has 38,987,920 shares outstanding.
What happened to CellSeed Inc.’s price movement after its last earnings report?
CellSeed Inc. reported an EPS of -¥7.31 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.305%.
Which hedge fund is a major shareholder of CellSeed Inc.?
Currently, no hedge funds are holding shares in JP:7776
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSeed Inc.
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―